{ "market" : {"NAME" : "U.S.", "ID" : "us_market", "TZ" : "ET", "TZOFFSET" : "-18000", "open" : "1265812230", "close" : "1265835630", "flags" : {}} , "STREAMER_SERVER" : "http://streamerapi.finance.yahoo.com","arrowAsChangeSign" : false,"throttleInterval": "1000"}

Send us feedback. Tell us what you think about the new Article Page. Send us feedback

Onyx Pharmaceuticals to Present at the Lazard Capital Markets 6th Annual Healthcare Conference

prnewswire

Related Quotes

SymbolPriceChange
ONXX29.05+0.59
Chart for ONYX Pharmaceuticals, Inc.
{"s" : "onxx","k" : "c10,l10,p20,t10","o" : "","j" : ""}
Press Release Source: Onyx Pharmaceuticals, Inc. On Wednesday November 11, 2009, 4:00 pm EST

EMERYVILLE, Calif., Nov. 11 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX - News) today announced that it will present at the Lazard Capital Markets 6th Annual Healthcare Conference on Wednesday, November 18, at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time). Interested parties may access a live webcast of the presentation on our website at:

http://www.onyx-pharm.com/view.cfm/32/Event-Calendar

It is recommended that listeners log on 15 minutes early in order to register and download any necessary software. For those unable to participate during the live webcast, a recorded replay of the presentation will be available one hour following the conclusion of the presentation through December 18, 2009.

Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer. The company, in collaboration with Bayer HealthCare Pharmaceuticals, Inc., is developing and marketing Nexavar®, a small molecule drug. Nexavar is currently approved for the treatment of liver cancer and advanced kidney cancer. Additionally, Nexavar is being investigated in several ongoing trials in a variety of tumor types. For more information about Onyx, visit the company's website at www.onyx-pharm.com.

Nexavar® (sorafenib) tablets is a registered trademark of Bayer HealthCare Pharmaceuticals.

Related Message Boards

Sponsored Links

Copyright © 2010 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.